Ms2.87-97
Ms2.87-97 has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, Apr 8, 2026: “A VLP-based immunogen that elicits selective anti-Myostatin antibodies, enhances muscle mass and strength, and reduces adiposity”.
1 paper studies it4 findingsUpdated
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Animals1
What did studies of ms2.87-97 find?
4Studies of ms2.87-97 measured 4 outcomes, among them fibrosis, muscle mass and grip strength.
Fibrosis
no changein mice1
1 study
Fibrosis
no changein mice1
Ms2.87-97 showed no clear effect on fibrosis in mice.
“histological analysis showed no change in myocardial collagen deposition (fibrosis).”
AnimalsVLP-based active immunotherapymyocardium
bioRxiv : the preprint server for biologyPreprint
Muscle mass
upin mice1
1 study
Muscle mass
upin mice1
Ms2.87-97 increases muscle mass in mice.
“upon dissection, they were found to have increased muscle mass.”
AnimalsVLP-based active immunotherapyskeletal muscle
bioRxiv : the preprint server for biologyPreprint
Grip strength
upin mice1
1 study
Grip strength
upin mice1
Ms2.87-97 improves grip strength in mice.
“MS2.87-97-treated mice also had significantly improved bodyweight-adjusted grip strength”
AnimalsVLP-based active immunotherapy
bioRxiv : the preprint server for biologyPreprint
Body fat percentage
downin mice1
1 study
Body fat percentage
downin mice1
Ms2.87-97 decreases body fat percentage in mice.
“Compared to controls, MS2.87-97-treated mice had less age-associated weight gain and exhibited significantly reduced body fat by DEXA scan.”
AnimalsVLP-based active immunotherapyadipose tissue
bioRxiv : the preprint server for biologyPreprint